A randomized, double blind, 12 week, parallel group, placebo controlled study of the efficacy and safety of RO4917523 in patients with Fragile X Syndrome
ClinicalTrials.gov Identifier: NCT01517698
This international multi-centre trial, run by Roche, aims to evaluate a new medication, RO4917523, for people aged 16-50 with Fragile X Syndrome. The Patrick Wild Centre is leading the research in the UK. There are three Scottish sites (Lothian, Glasgow and Tayside) which are now recruiting and other UK sites are planned.
Please contact Dr Andrew Stanfield if you would like more details.
Read more about Ongoing Treatment Trials by clicking here.